康寧傑瑞(09966.HK)JSKN003獲美國FDA孤兒藥資格認定
康寧傑瑞(09966.HK)公佈,旗下靶向人表皮生長因子受體2雙表位抗體偶聯藥物JSKN003,已獲得美國FDA授予孤兒藥資格認定,用於治療胃癌及胃食管結合部癌。公司預期,獲得認定將有利於該產品未來在美國的研發、註冊與商業化等方面獲得相關政策支持,包括研發費用資助、臨牀研究費用稅收減免、處方
藥用戶費用豁免、加速上市審評審批等,以及藥物獲批後有望獲得美國市場的七年獨佔權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.